Cytogenetic Responses
| . | IFN Arm (n = 100) . | Control Arm (n = 95) . |
|---|---|---|
| Evaluable patients | 97 | 86 |
| Early blast crisis | 5 (5%) | 2 (2%) |
| Early side effects | 11 (11%) | 2 (2%) |
| No response | 41 (42%) | 72 (84%) |
| Minimal response (35-95% Ph+) | 24 (25%) | 8 (9%) |
| Partial response (1-35% Ph+) | 7 (7%) | 2 (2%) |
| Complete response | 9 (9%) | 0 (0%) |
| Nonevaluable patients | 3 | 9 |
| Dry tap, Ph− | 1 | |
| No follow-up data | 3 | 8 |
| . | IFN Arm (n = 100) . | Control Arm (n = 95) . |
|---|---|---|
| Evaluable patients | 97 | 86 |
| Early blast crisis | 5 (5%) | 2 (2%) |
| Early side effects | 11 (11%) | 2 (2%) |
| No response | 41 (42%) | 72 (84%) |
| Minimal response (35-95% Ph+) | 24 (25%) | 8 (9%) |
| Partial response (1-35% Ph+) | 7 (7%) | 2 (2%) |
| Complete response | 9 (9%) | 0 (0%) |
| Nonevaluable patients | 3 | 9 |
| Dry tap, Ph− | 1 | |
| No follow-up data | 3 | 8 |